Patent application number | Description | Published |
20100173028 | PROCESS FOR PREPARING VITIS VINIFERA PIP EXTRACT AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS COMPRISING THE SAME - The present invention provides an improved process for preparing a | 07-08-2010 |
20120039911 | CD93 OR USE OF SOLUBLE FRAGMENT THEREOF - The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer. | 02-16-2012 |
20120172394 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS, CONTAINING REBAMIPIDE - The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg. | 07-05-2012 |
20120207725 | MESENCHYMAL STEM CELL INCORPORATING A NUCLEOTIDE SEQUENCE CODING TGFB, AND USES THEREOF - One or more specific examples of the present invention relate to a mesenchymal stem cell incorporating a nucleotide sequence coding TGFβ, and to the uses thereof. | 08-16-2012 |
20130017226 | TNF-A and TWEAK Dual Antagonist for the Prophylaxis and Treatment of Autoimmune DiseasesAANM Park; Young WooAACI DaejeonAACO KRAAGP Park; Young Woo Daejeon KRAANM Jo; Ki WonAACI Gyeonggi-doAACO KRAAGP Jo; Ki Won Gyeonggi-do KRAANM Yoo; Srok HoAACI DaejeonAACO KRAAGP Yoo; Srok Ho Daejeon KRAANM Yu; JungAACI DaejeonAACO KRAAGP Yu; Jung Daejeon KRAANM Kim; Dong JiAACI DaejeonAACO KRAAGP Kim; Dong Ji Daejeon KRAANM Yoon; Sun-HaAACI DaejeonAACO KRAAGP Yoon; Sun-Ha Daejeon KRAANM Song; Eun JungAACI DaejeonAACO KRAAGP Song; Eun Jung Daejeon KRAANM Lee; Eun KyungAACI Gyeonggi-doAACO KRAAGP Lee; Eun Kyung Gyeonggi-do KRAANM Oh; Jin MiAACI Gyeonggi-doAACO KRAAGP Oh; Jin Mi Gyeonggi-do KRAANM Cho; Kyu WonAACI SeoulAACO KRAAGP Cho; Kyu Won Seoul KRAANM Cho; Mi LaAACI SeoulAACO KRAAGP Cho; Mi La Seoul KRAANM Kim; Ho YounAACI SeoulAACO KRAAGP Kim; Ho Youn Seoul KRAANM Park; Mi KyungAACI Gyeonggi-doAACO KRAAGP Park; Mi Kyung Gyeonggi-do KRAANM Oh; Hye JwaAACI SeoulAACO KRAAGP Oh; Hye Jwa Seoul KRAANM Park; Jin SilAACI SeoulAACO KRAAGP Park; Jin Sil Seoul KRAANM Woo; Yun JuAACI SeoulAACO KRAAGP Woo; Yun Ju Seoul KRAANM Byun; Jae KyeongAACI Chungcheongbuk-doAACO KRAAGP Byun; Jae Kyeong Chungcheongbuk-do KRAANM Ryu; Jun GeolAACI Gangwon-doAACO KRAAGP Ryu; Jun Geol Gangwon-do KR - The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-α and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 01-17-2013 |
20130022642 | Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases - The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 01-24-2013 |
20130065920 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF OSTEOARTHRITIS CONTAINING REBAMIPIDE AS AN ACTIVE INGREDIENT - The present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg. | 03-14-2013 |
20130189240 | COMPOSITION CONTAINING PIAS3 AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER OR IMMUNE DISEASE - The present invention relates to a composition containing PIAS3 as an active ingredient for the prevention or treatment of cancer or immune disease. More specifically, the present invention relates to a composition containing the PIAS3 gene or an expressing protein thereof as an active ingredient for the prevention or treatment of cancer or immune disease, to an immunosuppressant composition, to a method for reducing or inhibiting undifferentiated T cells into Th17 cells using the PIAS3 gene or an expressing protein thereof, and to a method for activating regulatory T cells. | 07-25-2013 |
20140336220 | COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING REBAMIPIDE - The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with obesity, it shows excellent effects of reducing weight, reducing adipocyte, and reducing a total cholesterol content in the body, as compared with a non-administered control group, and also, it shows an excellent effect of suppressing differentiation of cytotoxic Th17 cells that generate and secrets inflammatory cytokine and an excellent effect of improving activity of regulatory T cells (Treg) capable of suppressing a function of abnormally activated immune cells and controlling an inflammatory reaction. Thus, the rebamipide compound can be used for producing a medicine and a functional food which can effectively treat obesity caused by abnormality of immune modulation. | 11-13-2014 |
20150051108 | KIT FOR MONITORING IMMUNE STATUS AFTER TRANSPLANT AND METHOD FOR MONITORING IMMUNE STATUS USING SAME - The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient. | 02-19-2015 |